Within the metastatic disease setting, the presence of KRAS/NRAS mutations provides resistance to cetuximab and panitumumab [21], while BRAFV600E mutation predicts response to anti-EGFR targeted therapies in combination with a BRAF inhibitor [22,23]. Here, NRAS is linked to metastatic neoplasm.